ACM
BLUE

Asymmetry Capital Management’s bluebird bio BLUE Stock Holding History

Asymmetry Capital Management’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,930
Closed -$1.53M – 36
2020
Q2 		$1.53M Buy
+1,930
New +$1.46M 1.17% 24

Other funds holding BLUE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Asymmetry Capital Management's BLUE Position: Q3 2020 in Review

Asymmetry Capital Management sold out of bluebird bio (BLUE) in Q3 2020, closing a stake of 1,930 shares — an estimated $1.53M sold.

Asymmetry Capital Management first reported a position in BLUE in Q2 2020 and held it in 1 quarter. The position peaked at $1.53M in Q2 2020. 275 funds tracked by Wall St. Rank hold BLUE as of Q3 2020.

  • Asymmetry Capital Management reported no remaining bluebird bio position as of Q3 2020 after selling out during the quarter.
  • Asymmetry Capital Management sold 1,930 bluebird bio shares in Q3 2020, an estimated $1.53M.
  • Asymmetry Capital Management first reported a position in bluebird bio in Q2 2020 and held it in 1 quarter.
  • Asymmetry Capital Management's bluebird bio position peaked at $1.53M in Q2 2020.
  • 275 funds tracked by Wall St. Rank held bluebird bio as of Q3 2020.

Based on Asymmetry Capital Management's 13F filing for Q3 2020, filed 12 Nov 2020.